Details of the Drug Combination

General Information of Drug Combination (ID: DCD4WJJ)

Drug Combination Name

Eltanexor oral Sitosterol

Indication

Disease Entry	Status	REF
Hepatoblastoma	Investigative	[1]

Component Drugs

Eltanexor oral DM7CLEZ

Sitosterol DM05DR0

N.A.

Small molecular drug

2D MOL

3D MOL

High-throughput Screening Result

Testing Cell Line: HB3

Zero Interaction Potency (ZIP) Score: 9.329

Bliss Independence Score: 8.919

Loewe Additivity Score: 2.613

LHighest Single Agent (HSA) Score: 1.652

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Eltanexor oral

Disease Entry	ICD 11	Status	REF
Colorectal cancer	2B91.Z	Phase 1/2	[2]
Myelodysplastic syndrome	2A37	Phase 1/2	[2]
Prostate cancer	2C82.0	Phase 1/2	[2]

Eltanexor oral Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Exportin-1 (XPO1)	TTCJUR4	XPO1_HUMAN	Inhibitor	[2]
------------------------------------------------------------------------------------

Indication(s) of Sitosterol

Disease Entry	ICD 11	Status	REF
Hyperlipidaemia	5C80	Approved	[3]

References

1	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015